The effect of differing gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer

John G. Phillips, Ayal A. Aizer, Ming Hui Chen, Danjie Zhang, Michelle S. Hirsch, Jerome P. Richie, Clare M. Tempany, Stephen Williams, John V. Hegde, Marian J. Loffredo, Anthony V. D'Amico

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

We provide evidence that differing Gleason scores (GSs) at biopsy (ComboGS) is associated with an approximately 80% decrease in the odds of upgrading and a 60% decrease in the risk of prostate cancer-specific mortality (PCSM) after definitive treatment. If validated, future randomized noninferiority studies evaluating deescalated treatment approaches in men with ComboGS could be considered. Introduction/Background: The GS is an established prostate cancer prognostic factor. Whether the presence of differing GSs at biopsy (eg, 4+3 and 3+3), which we term ComboGS, improves the prognosis that would be predicted based on the highest GS (eg, 4+3) because of decreased upgrading is unknown. Therefore, we evaluated the odds of upgrading at time of radical prostatectomy (RP) and the risk of PCSM when ComboGS was present versus absent. Patients and Methods: Logistic and competing risks regression were performed to assess the effect that ComboGS had on the odds of upgrading at time of RP in the index (n = 134) and validation cohorts (n = 356) and the risk of PCSM after definitive therapy in a long-term cohort (n = 666), adjusting for known predictors of these end points. We calculated and compared the area under the curve using a receiver operating characteristic analysis when ComboGS was included versus excluded from the upgrading models. Results: ComboGS was associated with decreased odds of upgrading (index: adjusted odds ratio [AOR], 0.14; 95% confidence interval [CI], 0.04-0.50; P = .003; validation: AOR, 0.24; 95% CI, 0.11-0.51; P <.001) and added significantly to the predictive value of upgrading for the in-sample index (P = .02), validation (P = .003), and out-of-sample prediction models (P = .002). ComboGS was also associated with a decreased risk of PCSM (adjusted hazard ratio, 0.40; 95% CI, 0.19-0.85; P = .02). Conclusion: Differing biopsy GSs are associated with a lower odds of upgrading and risk of PCSM. If validated, future randomized noninferiority studies evaluating deescalated treatment approaches in men with ComboGS could be considered.

Original languageEnglish (US)
Pages (from-to)e181-e187
JournalClinical Genitourinary Cancer
Volume12
Issue number5
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Neoplasm Grading
Prostatic Neoplasms
Biopsy
Mortality
Confidence Intervals
Prostatectomy
Odds Ratio
Therapeutics
ROC Curve
Area Under Curve

Keywords

  • ComboGS
  • Pathology
  • Prognostic factors
  • Prostate cancer-specific mortality
  • Radical prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Medicine(all)

Cite this

Phillips, J. G., Aizer, A. A., Chen, M. H., Zhang, D., Hirsch, M. S., Richie, J. P., ... D'Amico, A. V. (2014). The effect of differing gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer. Clinical Genitourinary Cancer, 12(5), e181-e187. https://doi.org/10.1016/j.clgc.2014.02.008

The effect of differing gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer. / Phillips, John G.; Aizer, Ayal A.; Chen, Ming Hui; Zhang, Danjie; Hirsch, Michelle S.; Richie, Jerome P.; Tempany, Clare M.; Williams, Stephen; Hegde, John V.; Loffredo, Marian J.; D'Amico, Anthony V.

In: Clinical Genitourinary Cancer, Vol. 12, No. 5, 2014, p. e181-e187.

Research output: Contribution to journalArticle

Phillips, JG, Aizer, AA, Chen, MH, Zhang, D, Hirsch, MS, Richie, JP, Tempany, CM, Williams, S, Hegde, JV, Loffredo, MJ & D'Amico, AV 2014, 'The effect of differing gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer', Clinical Genitourinary Cancer, vol. 12, no. 5, pp. e181-e187. https://doi.org/10.1016/j.clgc.2014.02.008
Phillips, John G. ; Aizer, Ayal A. ; Chen, Ming Hui ; Zhang, Danjie ; Hirsch, Michelle S. ; Richie, Jerome P. ; Tempany, Clare M. ; Williams, Stephen ; Hegde, John V. ; Loffredo, Marian J. ; D'Amico, Anthony V. / The effect of differing gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer. In: Clinical Genitourinary Cancer. 2014 ; Vol. 12, No. 5. pp. e181-e187.
@article{c8096022dd754533a2d36d71102e1ca2,
title = "The effect of differing gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer",
abstract = "We provide evidence that differing Gleason scores (GSs) at biopsy (ComboGS) is associated with an approximately 80{\%} decrease in the odds of upgrading and a 60{\%} decrease in the risk of prostate cancer-specific mortality (PCSM) after definitive treatment. If validated, future randomized noninferiority studies evaluating deescalated treatment approaches in men with ComboGS could be considered. Introduction/Background: The GS is an established prostate cancer prognostic factor. Whether the presence of differing GSs at biopsy (eg, 4+3 and 3+3), which we term ComboGS, improves the prognosis that would be predicted based on the highest GS (eg, 4+3) because of decreased upgrading is unknown. Therefore, we evaluated the odds of upgrading at time of radical prostatectomy (RP) and the risk of PCSM when ComboGS was present versus absent. Patients and Methods: Logistic and competing risks regression were performed to assess the effect that ComboGS had on the odds of upgrading at time of RP in the index (n = 134) and validation cohorts (n = 356) and the risk of PCSM after definitive therapy in a long-term cohort (n = 666), adjusting for known predictors of these end points. We calculated and compared the area under the curve using a receiver operating characteristic analysis when ComboGS was included versus excluded from the upgrading models. Results: ComboGS was associated with decreased odds of upgrading (index: adjusted odds ratio [AOR], 0.14; 95{\%} confidence interval [CI], 0.04-0.50; P = .003; validation: AOR, 0.24; 95{\%} CI, 0.11-0.51; P <.001) and added significantly to the predictive value of upgrading for the in-sample index (P = .02), validation (P = .003), and out-of-sample prediction models (P = .002). ComboGS was also associated with a decreased risk of PCSM (adjusted hazard ratio, 0.40; 95{\%} CI, 0.19-0.85; P = .02). Conclusion: Differing biopsy GSs are associated with a lower odds of upgrading and risk of PCSM. If validated, future randomized noninferiority studies evaluating deescalated treatment approaches in men with ComboGS could be considered.",
keywords = "ComboGS, Pathology, Prognostic factors, Prostate cancer-specific mortality, Radical prostatectomy",
author = "Phillips, {John G.} and Aizer, {Ayal A.} and Chen, {Ming Hui} and Danjie Zhang and Hirsch, {Michelle S.} and Richie, {Jerome P.} and Tempany, {Clare M.} and Stephen Williams and Hegde, {John V.} and Loffredo, {Marian J.} and D'Amico, {Anthony V.}",
year = "2014",
doi = "10.1016/j.clgc.2014.02.008",
language = "English (US)",
volume = "12",
pages = "e181--e187",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - The effect of differing gleason scores at biopsy on the odds of upgrading and the risk of death from prostate cancer

AU - Phillips, John G.

AU - Aizer, Ayal A.

AU - Chen, Ming Hui

AU - Zhang, Danjie

AU - Hirsch, Michelle S.

AU - Richie, Jerome P.

AU - Tempany, Clare M.

AU - Williams, Stephen

AU - Hegde, John V.

AU - Loffredo, Marian J.

AU - D'Amico, Anthony V.

PY - 2014

Y1 - 2014

N2 - We provide evidence that differing Gleason scores (GSs) at biopsy (ComboGS) is associated with an approximately 80% decrease in the odds of upgrading and a 60% decrease in the risk of prostate cancer-specific mortality (PCSM) after definitive treatment. If validated, future randomized noninferiority studies evaluating deescalated treatment approaches in men with ComboGS could be considered. Introduction/Background: The GS is an established prostate cancer prognostic factor. Whether the presence of differing GSs at biopsy (eg, 4+3 and 3+3), which we term ComboGS, improves the prognosis that would be predicted based on the highest GS (eg, 4+3) because of decreased upgrading is unknown. Therefore, we evaluated the odds of upgrading at time of radical prostatectomy (RP) and the risk of PCSM when ComboGS was present versus absent. Patients and Methods: Logistic and competing risks regression were performed to assess the effect that ComboGS had on the odds of upgrading at time of RP in the index (n = 134) and validation cohorts (n = 356) and the risk of PCSM after definitive therapy in a long-term cohort (n = 666), adjusting for known predictors of these end points. We calculated and compared the area under the curve using a receiver operating characteristic analysis when ComboGS was included versus excluded from the upgrading models. Results: ComboGS was associated with decreased odds of upgrading (index: adjusted odds ratio [AOR], 0.14; 95% confidence interval [CI], 0.04-0.50; P = .003; validation: AOR, 0.24; 95% CI, 0.11-0.51; P <.001) and added significantly to the predictive value of upgrading for the in-sample index (P = .02), validation (P = .003), and out-of-sample prediction models (P = .002). ComboGS was also associated with a decreased risk of PCSM (adjusted hazard ratio, 0.40; 95% CI, 0.19-0.85; P = .02). Conclusion: Differing biopsy GSs are associated with a lower odds of upgrading and risk of PCSM. If validated, future randomized noninferiority studies evaluating deescalated treatment approaches in men with ComboGS could be considered.

AB - We provide evidence that differing Gleason scores (GSs) at biopsy (ComboGS) is associated with an approximately 80% decrease in the odds of upgrading and a 60% decrease in the risk of prostate cancer-specific mortality (PCSM) after definitive treatment. If validated, future randomized noninferiority studies evaluating deescalated treatment approaches in men with ComboGS could be considered. Introduction/Background: The GS is an established prostate cancer prognostic factor. Whether the presence of differing GSs at biopsy (eg, 4+3 and 3+3), which we term ComboGS, improves the prognosis that would be predicted based on the highest GS (eg, 4+3) because of decreased upgrading is unknown. Therefore, we evaluated the odds of upgrading at time of radical prostatectomy (RP) and the risk of PCSM when ComboGS was present versus absent. Patients and Methods: Logistic and competing risks regression were performed to assess the effect that ComboGS had on the odds of upgrading at time of RP in the index (n = 134) and validation cohorts (n = 356) and the risk of PCSM after definitive therapy in a long-term cohort (n = 666), adjusting for known predictors of these end points. We calculated and compared the area under the curve using a receiver operating characteristic analysis when ComboGS was included versus excluded from the upgrading models. Results: ComboGS was associated with decreased odds of upgrading (index: adjusted odds ratio [AOR], 0.14; 95% confidence interval [CI], 0.04-0.50; P = .003; validation: AOR, 0.24; 95% CI, 0.11-0.51; P <.001) and added significantly to the predictive value of upgrading for the in-sample index (P = .02), validation (P = .003), and out-of-sample prediction models (P = .002). ComboGS was also associated with a decreased risk of PCSM (adjusted hazard ratio, 0.40; 95% CI, 0.19-0.85; P = .02). Conclusion: Differing biopsy GSs are associated with a lower odds of upgrading and risk of PCSM. If validated, future randomized noninferiority studies evaluating deescalated treatment approaches in men with ComboGS could be considered.

KW - ComboGS

KW - Pathology

KW - Prognostic factors

KW - Prostate cancer-specific mortality

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84922658718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922658718&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2014.02.008

DO - 10.1016/j.clgc.2014.02.008

M3 - Article

C2 - 24721618

AN - SCOPUS:84922658718

VL - 12

SP - e181-e187

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 5

ER -